Li K C, Cheng S Y, Du J, Li J
Departmentof Oncology, Tianyou Hospital Affiliated to Tongji University, Shanghai 200331, China.
Zhonghua Zhong Liu Za Zhi. 2016 Oct 23;38(10):721-724. doi: 10.3760/cma.j.issn.0253-3766.2016.10.001.
Gastric cancer is one of the major causes of cancer-related deaths. Many patients with metastatic gastric cancer after first-line chemotherapy received salvage chemotherapy in routine clinical practice. Recent phase Ⅲ trials demonstrated substantial prolongation of overall survival to support this chemotherapy or targeted therapy as a second-line treatment. Both ramucirumab monotherapy and ramucirumab plus paclitaxel were approved by FDA in patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma. In addition, paclitaxel, irinotecan, or docetaxel monotherapy is also recommended for preferred regimens. This review will summarize chemotherapy or targeted therapy as a second-line treatment in advanced gastric cancer.
胃癌是癌症相关死亡的主要原因之一。在常规临床实践中，许多一线化疗后出现转移性胃癌的患者接受了挽救性化疗。近期的Ⅲ期试验表明，总生存期显著延长，支持这种化疗或靶向治疗作为二线治疗。雷莫西尤单抗单药治疗以及雷莫西尤单抗联合紫杉醇均获美国食品药品监督管理局（FDA）批准，用于治疗先前接受过治疗的晚期胃癌或胃食管交界腺癌患者。此外，紫杉醇、伊立替康或多西他赛单药治疗也被推荐为首选方案。本综述将总结晚期胃癌二线治疗中的化疗或靶向治疗。
